Context

Polyphenols and Polyunsaturated fatty acids (PUFAs) were both studied for their potential therapeutical role. Polyphenols are natural anti-oxidative compounds : they are used for the treatment of cancer, diabetes, chronic, and cardiovascular diseases owing to their antioxidants and anti-inflammatory properties. A lot of polyphenols are naturally present in our diet. Some of them have the structure to reduce also Carbonyl stress. PUFAs are bioactive lipids which modulate inflammation and immunity. They gained recognition in nutritional therapy and are recommended dietary supplements for several pathologies including AMD. Antioxidant therapies may help in the fight against neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis). However BOTH Carbonyl and Oxidative stresses are involved in physiopathology of macula degeneration (age-related macula degeneration and Stargardt disease), and BOTH should be reduced to fight against macular dystrophies.

Benefits

The research team has been working on the Stargardt disease for many years and in this context has developed a series of lipophenolic compounds (patent families 1 & 3) able to reduce BOTH Carbonyl and Oxidative Stresses, with the aim of developing a new therapeutic approach against Stargardt disease and potentially applicable on AMD and neurodegenerative diseases. In parallel, they also demonstrated that one lipophenolic compounds (patent family 2), while not able to reduce Carbonyl and Oxidative stress, has an original mechanism of action by inhibiting MMP-9 pathways. This compound can also be applied in a wide range of therapeutic opportunities.

Applications

Patent families 1 & 3 : Stargard Disease, AMD (age-related macula degeneration), Neurodegenerative diseases (Alzheimer, Parkinson) Patent family 2 to position on therapeutic indications not selected yet, as modulator of MMP-9